GO
Loading...

Enter multiple symbols separated by commas

Johnson & Johnson

More

  • *First-quarter GDP revised down to show contraction. *GDP shrinks at a 0.7 percent annual rate. WASHINGTON, May 29- The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

  • *First-quarter GDP revised down to show contraction. *GDP shrinks at a 0.7 percent annual rate. WASHINGTON, May 29- The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls and a resurgent dollar, but activity has rebounded modestly.

  • NEW YORK, May 28- Visa Inc's public warning to FIFA that it may end its sponsorship if world soccer's governing body does not quickly clean up its act will likely prompt other sponsors to take a tough stance as a major corruption scandal involving FIFA unfolds, brand experts said. After U.S. prosecutors indicted nine FIFA officials and five sports media and...

  • May 28- A Delaware jury on Thursday ordered Boston Scientific to pay $100 million to a woman who said she was injured by transvaginal mesh, a device that is the subject of more than 25,000 lawsuits against the company. The 51- year old Newark, Delaware- resident was implanted with Boston Scientific's Pinnacle and Advantage Fit mesh products in 2009, to treat...

  • J&J accepts offer from Cardinal Health for Cordis unit Thursday, 28 May 2015 | 8:23 AM ET

    NEW YORK— Health care giant Johnson& Johnson has formally accepted a $1.94 billion offer to sell its Cordis heart devices unit to Cardinal Health. Cordis has operations in more than 50 countries, including China, Japan, Germany, Italy, France, the U.K. and Brazil. Cardinal Health had previously said that it expects the deal to add more than 20 cents per share to its...

  • FBI probing J&J on uterine surgery device: Report Wednesday, 27 May 2015 | 6:32 PM ET

    The FBI is looking into what Johnson & Johnson knew about the risks posed by a surgical tool, according to a report by the WSJ.

  • May 27- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson& Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported. A J&J spokesman said the company has not been contacted by the FBI regarding its Ethicon morcellation devices.

  • May 27- The Federal Bureau of Investigation is looking into what Johnson& Johnson knew about the risks posed by a surgical tool in spreading uterine cancer before withdrawing its version of the device last year, the Wall Street Journal reported. J&J said in July that it would ask doctors to return the device, called laparoscopic power morcellator, which is used to...

  • Utah defends contentious law on contact lens price-fixing Wednesday, 27 May 2015 | 12:25 PM ET

    SALT LAKE CITY— Utah state attorneys have asked an appeals court to clear the way for a contentious law that bans price fixing by contact lens makers and could have wide-ranging implications for the $4 billion industry. They were joined by the discount retailers Costco and Utah- based 1-800 Contacts. Suing to block the law are lens makers Alcon Laboratories,...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed about 1 percent lower as investors eyed renewed strength in the dollar and data that could strengthen the case for a rate hike.

  • Abbvie completes $21 billion buyout of Pharmacyclics Tuesday, 26 May 2015 | 11:15 AM ET

    NEW YORK— Abbvie has completed its $21 billion buyout of Pharmacyclics. The buyout adds another major revenue producer to Abbvie's portfolio, which already includes the world's top-selling drug, Humira. Pharmacyclics Inc. will become a subsidiary of Abbvie and operate from its Sunnyvale, California headquarters.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • SACRAMENTO, Calif.— The California Assembly on Friday approved one of the nation's toughest bans on plastic, exfoliating microbeads that are polluting waterways. Manufacturers already have pledged to phase out the materials, including L'Oreal, Unilever and Johnson& Johnson, and use natural alternatives such as apricot shells and cocoa beans.

  • NEW YORK— Abbvie Inc. specified the stock and cash breakdown on Thursday of its previously announced $21 billion buyout of Pharmacyclics Inc.. The drugmaker said the mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie...

  • CVS paying $10.4B in cash for drug distributor Omnicare Thursday, 21 May 2015 | 7:18 AM ET

    CVS Health will pay more than $10 billion for pharmaceutical distributor Omnicare in a deal primed to feed its fast-growing specialty drug business and tap a lucrative and growing market: care for the elderly. Omnicare's long-term care business operates in 47 states and the District of Columbia. Cincinnati- based Omnicare's core business involves...

  • J&J can weather new biotech threat: Analyst Wednesday, 20 May 2015 | 4:33 PM ET
    Johnson & Johnson

    Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.

  • The hep C challenge   Wednesday, 20 May 2015 | 3:37 PM ET
    The hep C challenge

    Analysts tend to leave out Johnson & Johnson's hepatitis C drug out of the company's growth projections. Details, with NBC's Meg Tirrell.

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • 19)@ (Corrects paragraphs 2 and 3 to say J&J's $1.1 billion potential payments include equity investment of $225 million and are not in addition to the $1.1 billion). May 19 (Reuters)- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and...

  • Achillion sinks after partnering with Johnson & Johnson Wednesday, 20 May 2015 | 11:38 AM ET

    Investors started shedding Achillion shares early Wednesday, less than a day after the drugmaker announced a partnership with pharmaceutical giant Johnson& Johnson that snuffed out the prospect of a near-term acquisition. Achillion representatives said during a conference call that Johnson& Johnson will make a $225 million equity investment in their...